Canaccord lowers AngioDynamics stock price target on EBITDA guidance By Investing.com

AngioDynamics beat Q3 fiscal 2026 estimates with EPS of -$0.07 vs -$0.09 expected (22.22% surprise) and revenue of $78.4M vs $76.7M consensus. Canaccord lowered its price target to $16 from $18 but kept a Buy, while the stock traded at $10.53 and showed a pre-market decline. Management set FY26 adjusted EBITDA guidance of $10M–$12M and Canaccord now models Q4 adjusted EBITDA of $0.8M (down from prior $1.8M); the company will accelerate inventory ahead of sterilization partner maintenance and a manufacturing move to Costa Rica, using an incremental $3M–$5M of cash and pressuring Q4 gross margins. Product-line trends were positive (NanoKnife +20%+ sales growth), but the company remains unprofitable.

Analysis

The company’s near-term actions—pulling forward production ahead of a partner maintenance window and a manufacturing relocation—create a classic pulled-forward-sales / working-capital squeeze: revenue recognition may look lumpy while gross margins absorb higher inventory and one-time conversion costs. That pattern tends to compress adjusted EBITDA disproportionately versus revenue because fixed-cost absorption and sterilization throughput are binary around the maintenance window and transfer ramp.

NanoKnife’s disposable + capital mix is the strategic optionality here: if procedure volumes and recent payer coding trends persist, disposables convert into annuity-like high-margin revenue that can re-rate the multiple over 12–24 months. However, payer reversals, coding audits, or slower hospital capital cycles are low-probability but high-impact tail risks that would flatten adoption and reverse optionality quickly.

Execution risk on the Costa Rica transition is the key second-order effect investors underappreciate: successful transfer reduces unit costs and raises long-term gross margins, but any inspection failure, yield shortfall, or cross-border logistics hiccup can create a multi-quarter revenue/margin gap and force incremental cash consumption. The market is implicitly discounting that execution; the fulcrum for re-rating is visibility around sterilization uptime and early post-transfer yield metrics.

Near-term catalyst set to watch: sterilization partner completion, first months of production out of the new facility, and sequential EBITDA conversion. These three datapoints will compress uncertainty quickly — if they come in clean the stock will rerate materially; if not, downside is concentrated and fast given current leverage in the P&L.

Key Decisions for Investors

• Tactical option spread (bullish, defined risk): Buy a 9-month ANGO 30-delta call and sell a 9-month ANGO 10-delta call to create a debit call spread sized to 1–2% of NAV. Rationale: captures upside from durable disposable adoption and margin recovery while capping premium outlay; expected payoff skewed if sterilization and Costa Rica milestones print positively within 6–9 months. Max loss = premium paid; target 2–4x payoff if adoption continues.
• Structured equity + hedge (moderate bullish): Establish a 2% NAV long-stock position in ANGO and buy a 6-month put at ~25% downside to cap tail risk. Rationale: preserves upside optionality to recurring disposables over 12 months while limiting cash-flow/EBITDA miss exposure from the inventory/margin squeeze. Risk/Reward: pay ~2–3% NAV in put premium to limit drawdown; upside targeted +50–80% conditional on successful execution.
• Relative-value pair (idiosyncratic long vs sector hedge): Long ANGO vs short a large-cap diversified med-tech (e.g., BSX or MDT) sized to net neutral beta, 6–12 month horizon. Rationale: isolates ANGO’s execution and reimbursement optionality versus macro medical device exposure; profitable if ANGO’s procedure adoption outpaces peers. Risks: sector-wide multiple expansion would blunt the trade—keep position small (1–2% NAV) and monitor sector flows.
• Event/defensive hedge (protective if execution slips): Buy a 3-month ANGO 10% OTM put and sell a nearer-term 20% OTM put (put bear spread) sized to 0.5–1% NAV as inexpensive insurance ahead of the sterilization/transfer milestones. Rationale: cheap downside protection against a discrete operational miss while retaining some premium financing. Max loss = width of spread less premium received; payoff asymmetric if inspection or sterilization delays are announced.